These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 21737227)

  • 1. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes.
    Rutkowski P; Bylina E; Wozniak A; Nowecki ZI; Osuch C; Matlok M; Switaj T; Michej W; Wroński M; Głuszek S; Kroc J; Nasierowska-Guttmejer A; Joensuu H
    Eur J Surg Oncol; 2011 Oct; 37(10):890-6. PubMed ID: 21737227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts.
    Joensuu H; Vehtari A; Riihimäki J; Nishida T; Steigen SE; Brabec P; Plank L; Nilsson B; Cirilli C; Braconi C; Bordoni A; Magnusson MK; Linke Z; Sufliarsky J; Federico M; Jonasson JG; Dei Tos AP; Rutkowski P
    Lancet Oncol; 2012 Mar; 13(3):265-74. PubMed ID: 22153892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor.
    Rutkowski P; Nowecki ZI; Michej W; Debiec-Rychter M; Woźniak A; Limon J; Siedlecki J; Grzesiakowska U; Kakol M; Osuch C; Polkowski M; Głuszek S; Zurawski Z; Ruka W
    Ann Surg Oncol; 2007 Jul; 14(7):2018-27. PubMed ID: 17473953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.
    Cao H; Zhang Y; Wang M; Shen DP; Sheng ZY; Ni XZ; Wu ZY; Liu Q; Shen YY; Song YY
    Chin Med J (Engl); 2010 Jan; 123(2):131-6. PubMed ID: 20137358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
    Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
    Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which is the optimal risk stratification system for surgically treated localized primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors and a proposal for a modified Armed Forces Institute of Pathology risk criteria.
    Goh BK; Chow PK; Yap WM; Kesavan SM; Song IC; Paul PG; Ooi BS; Chung YF; Wong WK
    Ann Surg Oncol; 2008 Aug; 15(8):2153-63. PubMed ID: 18546045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection.
    Rutkowski P; Wozniak A; Dębiec-Rychter M; Kąkol M; Dziewirski W; Zdzienicki M; Ptaszynski K; Jurkowska M; Limon J; Siedlecki JA
    Cancer; 2011 Nov; 117(21):4916-24. PubMed ID: 21456019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib.
    Tielen R; Verhoef C; van Coevorden F; Gelderblom H; Sleijfer S; Hartgrink HH; Bonenkamp JJ; van der Graaf WT; de Wilt JH
    Eur J Surg Oncol; 2013 Feb; 39(2):150-5. PubMed ID: 23084087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables.
    Rossi S; Miceli R; Messerini L; Bearzi I; Mazzoleni G; Capella C; Arrigoni G; Sonzogni A; Sidoni A; Toffolatti L; Laurino L; Mariani L; Vinaccia V; Gnocchi C; Gronchi A; Casali PG; Dei Tos AP
    Am J Surg Pathol; 2011 Nov; 35(11):1646-56. PubMed ID: 21997685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population-based study of the diagnosis and treatment of gastrointestinal stromal tumours.
    Bümming P; Ahlman H; Andersson J; Meis-Kindblom JM; Kindblom LG; Nilsson B
    Br J Surg; 2006 Jul; 93(7):836-43. PubMed ID: 16705644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Gastrointestinal stromal tumour: our experience].
    Versaci A; Macrì A; Ieni A; Terranova M; Leonello G; Saladino E; Speciale G; Famulari C
    Chir Ital; 2009; 61(2):161-9. PubMed ID: 19536989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Audit of a series of 40 gastrointestinal stromal tumour cases.
    Hinz S; Pauser U; Egberts JH; Schafmayer C; Tepel J; Fändrich F
    Eur J Surg Oncol; 2006 Dec; 32(10):1125-9. PubMed ID: 16859873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multi-centre analysis of the impact of updated risk stratification on follow-up of gastric gastro-intestinal stromal tumours in the post-imatinib era.
    Reece-Smith AM; MacGoey P; Shah MA; Leeder P; Andrew DR; McCulloch T; Parsons SL
    Eur J Surg Oncol; 2012 Jun; 38(6):484-9. PubMed ID: 22342866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS).
    Martín J; Poveda A; Llombart-Bosch A; Ramos R; López-Guerrero JA; García del Muro J; Maurel J; Calabuig S; Gutierrez A; González de Sande JL; Martínez J; De Juan A; Laínez N; Losa F; Alija V; Escudero P; Casado A; García P; Blanco R; Buesa JM;
    J Clin Oncol; 2005 Sep; 23(25):6190-8. PubMed ID: 16135486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence After Resection.
    Guérin A; Sasane M; Keir CH; Gauthier G; Macalalad AR; Wu EQ; Conley AP
    JAMA Oncol; 2015 Sep; 1(6):797-805. PubMed ID: 26204106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months.
    Jiang WZ; Guan GX; Lu HS; Yang YH; Kang DY; Huang HG
    J Surg Oncol; 2011 Dec; 104(7):760-4. PubMed ID: 21713778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.
    Gold JS; Gönen M; Gutiérrez A; Broto JM; García-del-Muro X; Smyrk TC; Maki RG; Singer S; Brennan MF; Antonescu CR; Donohue JH; DeMatteo RP
    Lancet Oncol; 2009 Nov; 10(11):1045-52. PubMed ID: 19793678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours.
    Aparicio T; Boige V; Sabourin JC; Crenn P; Ducreux M; Le Cesne A; Bonvalot S
    Eur J Surg Oncol; 2004 Dec; 30(10):1098-103. PubMed ID: 15522557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An audit of surgical management of gastrointestinal stromal tumours (GIST).
    Bucher P; Egger JF; Gervaz P; Ris F; Weintraub D; Villiger P; Buhler LH; Morel P
    Eur J Surg Oncol; 2006 Apr; 32(3):310-4. PubMed ID: 16414236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
    Blay JY; Le Cesne A; Ray-Coquard I; Bui B; Duffaud F; Delbaldo C; Adenis A; Viens P; Rios M; Bompas E; Cupissol D; Guillemet C; Kerbrat P; Fayette J; Chabaud S; Berthaud P; Perol D
    J Clin Oncol; 2007 Mar; 25(9):1107-13. PubMed ID: 17369574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.